Join MassBio and Precision for a one-of-a-kind panel discussion with a unique group of experts in cell and gene therapy studies. These pioneers have been involved in multiple programs that led to FDA-approved cell and gene therapies. They will share lessons learned from experience, giving you actionable insights on every stage of a trial—from the lab, to studies, to logistics and biomanufacturing.
Topics to be covered include:
- Creating an effective study plan, spanning sample center study, manufacturing QC, and contingency plans to anticipate disruption
- Managing safety and toxicity, including medical and safety signals pre- and post-infusion
- Utilizing the latest techniques to monitor both distribution and persistence of the cellular or gene therapy
- Establishing a biomanufacturing strategy and considerations for building a facility
The discussion will be followed by a live Q&A.
—
Megan Liles (Moderator)
Executive Director, Operational Strategy and Feasibility, Precision for Medicine
Deborah Phippard, PhD
Global Head, Research Services, Precision for Medicine
Clare Sarvary Fourrier
Senior Vice President, Global Operational Strategy, Precision for Medicine
Tony Khoury
Executive Vice President, Project Farma
Paul Rennert
President and CSO, Aleta Biotherapeutics
—